BostonGene agreed with Kyoto University to apply its AI‑powered molecular platform to identify biomarkers and immune pathways in esophageal squamous cell carcinoma, combining genomic and transcriptomic data from prior clinical trials to guide combination immunotherapy and chemoradiotherapy strategies. At the same time Dyno Therapeutics showcased AI‑driven capsid engineering and 'AI agents' for end‑to‑end genetic medicine design at its Genetic Agency Technology Conference. These developments underscore growing industry emphasis on AI to accelerate target discovery, patient stratification, and delivery vector engineering.